000 03388nam a22005175i 4500
001 978-3-642-25758-2
003 DE-He213
005 20140220083306.0
007 cr nn 008mamaa
008 121009s2012 gw | s |||| 0|eng d
020 _a9783642257582
_9978-3-642-25758-2
024 7 _a10.1007/978-3-642-25758-2
_2doi
050 4 _aRM1-950
072 7 _aMMG
_2bicssc
072 7 _aMED071000
_2bisacsh
082 0 4 _a615
_223
100 1 _aGeyer, Mark A.
_eeditor.
245 1 0 _aNovel Antischizophrenia Treatments
_h[electronic resource] /
_cedited by Mark A. Geyer, Gerhard Gross.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2012.
300 _aX, 455 p. 20 illus., 15 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aHandbook of Experimental Pharmacology,
_x0171-2004 ;
_v213
505 0 _aPreface -- Clinical instruments to evaluate and guide treatment in schizophrenia -- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders -- Nicotinic mechanisms in psychotic disorders -- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia -- Inhibitors of glycine transport as potential new treatments in schizophrenia -- The role of glutamate in schizophrenia -- Metabotropic glutamate receptors as targets for new treatments in schizophrenia -- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions -- Phosphodiesterase inhibitors as potential new treatments in schizophrenia -- Disease modifying approaches to schizophrenia -- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia -- Transgenic animals reflecting aspects of schizophrenia -- Behavioral animal models of pro-cognitive treatments for schizophrenia. .
520 _aThis volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
650 0 _aMedicine.
650 0 _aToxicology.
650 0 _aPharmacy.
650 0 _aPsychopharmacology.
650 0 _aApplied psychology.
650 1 4 _aBiomedicine.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aPharmacy.
650 2 4 _aPsychopharmacology.
650 2 4 _aBiological Psychology.
700 1 _aGross, Gerhard.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642257575
830 0 _aHandbook of Experimental Pharmacology,
_x0171-2004 ;
_v213
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-25758-2
912 _aZDB-2-SBL
999 _c102482
_d102482